Stefansson Bergur
AstraZeneca - R&D Mölndal, Sweden - Göteborg, Sweden.
Lakartidningen. 2015 Mar 10;112:DDRS.
The main causes for renal anemia are insufficient erythropoietin production and absolute and/or functional iron deficiency. Absolute iron deficiency occurs with blood losses (most common are gastro-intestinal bleedings and hemodialysis treatments) or inadequate iron absorption in the gut (mainly due to increased circulating hepcidin or treatment with erythropoiesis stimulating agents). The explanation for functional iron deficiency is the high level of circulating hepcidin found in chronic kidney disease patients. The transmembrane iron transporter ferroportin is internalized and degraded by hepcidin with subsequent decreased iron absorption from the gut and reduced mobilization from iron storing cells. Thus, the bioavailability of iron is decreased despite normal or high total iron content. The diagnosis of iron deficiency in chronic kidney disease can be problematic because inflammation is common, leading to false high circulating ferritin and false low transferrin saturation. Treatment with iron is recommended in chronic kidney disease patients to prevent or minimize anemia symptoms or to reduce the need for treatment with erythropoiesis stimulating agents or blood transfusions. Intravenous iron is recommended in patients on dialysis treatment but in non-dialysis patients, a 1-3 month trial of oral iron can be tried. However, this is seldom sufficient in patients treated with erythropoiesis stimulating agents.
肾性贫血的主要原因是促红细胞生成素产生不足以及绝对性和/或功能性缺铁。绝对性缺铁发生于失血(最常见的是胃肠道出血和血液透析治疗)或肠道铁吸收不足(主要由于循环中的铁调素增加或使用促红细胞生成刺激剂治疗)。功能性缺铁的原因是慢性肾脏病患者循环中铁调素水平较高。跨膜铁转运蛋白铁转运蛋白被铁调素内化并降解,随后肠道铁吸收减少,铁储存细胞的铁动员减少。因此,尽管总铁含量正常或较高,但铁的生物利用度降低。慢性肾脏病中铁缺乏的诊断可能存在问题,因为炎症很常见,会导致循环铁蛋白假性升高和转铁蛋白饱和度假性降低。建议对慢性肾脏病患者进行铁剂治疗,以预防或减轻贫血症状,或减少使用促红细胞生成刺激剂或输血治疗的需求。对于接受透析治疗的患者,建议静脉补铁,但对于非透析患者,可以尝试进行1 - 3个月的口服铁剂试验。然而,对于接受促红细胞生成刺激剂治疗的患者,这很少足够。